Engineering the Baculovirus Genome to Produce Galactosylated Antibodies in Lepidopteran Cells

Nowadays, recombinant proteins are used with great success for the treatment of a variety of medical conditions, such as cancer, autoimmune, and infectious diseases. Several expression systems have been developed to produce human proteins, but one of their most critical limitations is the addition of truncated or nonhuman glycans to the recombinant molecules. The presence of such glycans can be deleterious as they may alter the protein physicochemical properties (e.g., solubility, aggregation), its half-life, and its immunogenicity due to the unmasking of epitopes.
Source: Springer protocols feed by Pharmacology/Toxicology - Category: Drugs & Pharmacology Source Type: news